A proof-of-concept study to investigate the radiolabelling of human mesenchymal and hematopoietic stem cells with [89Zr]Zr-Df-Bz-NCS
Successful <sup>89</sup>Zr-MSC and <sup>89</sup>Zr-HSPC labelling was achieved, which underlines the prospects for in vivo cell tracking studies with positron emission tomography. In vitro investigations with larger sample sizes and preclinical studies are recommended.
Authors
- Michael S. Pepper (ORCID: https://orcid.org/0000-0001-6406-2380)
- Ömer Aras (ORCID: https://orcid.org/0000-0003-1758-0542)
- Thomas Ebenhan (ORCID: https://orcid.org/0000-0002-2038-7324)
- Juanita Mellet (ORCID: https://orcid.org/0000-0002-0109-9853)
- Maryke Lundie (ORCID: https://orcid.org/0000-0002-0507-141X)
- Beverley Summers (ORCID: https://orcid.org/0000-0001-7852-8858)
- Kandasamy G. Moodley (ORCID: https://orcid.org/0000-0001-8223-3649)
- Jan Rijn Zeevaart (ORCID: https://orcid.org/0000-0003-0794-3012)
- Chrisna Durandt (ORCID: https://orcid.org/0000-0002-5679-4669)
Institutions
- South African Medical Research Council (ZA)
- Memorial Sloan Kettering Cancer Center (US)
- South African Nuclear Energy Corporation (South Africa) (ZA)
- North-West University (ZA)
- Sefako Makgatho Health Sciences University (ZA)
- Amita Health (US)
- Climate Resilience Infrastructure Development Facility (ZA)
- University of Pretoria (ZA)
Publication Details
- Journal
- EJNMMI Radiopharmacy and Chemistry
- Published
- 2024-11-29
- DOI
- https://doi.org/10.1186/s41181-024-00311-w
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00